Identification of Transporters Involved in Beraprost Sodium Transport In Vitro

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 42, Issue 1, 2017, Pages 117-128

  Oshida, Keiyu ^a   Shimamura, Masahiro ^a   Seya, Kazuhiro ^b   Ando, Akihiro ^a   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BERAPROST; BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; BROMSULFOPHTHALEIN; CARRIER PROTEINS AND BINDING PROTEINS; CYCLOSPORIN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER B; ORGANIC CATION TRANSPORTER 2; PROBENECID; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; URATE TRANSPORTER; VERAPAMIL; CARRIER PROTEIN; PROSTACYCLIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TRANSPORT; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE VESICLE; NONHUMAN; PHARMACOKINETICS; PROTEIN EXPRESSION; SUBSTRATE CONCENTRATION; TRANSPORT ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; DRUG INTERACTION; METABOLISM; PIG; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DRUG INTERACTIONS; EPOPROSTENOL; HUMANS; MEMBRANE TRANSPORT PROTEINS; SWINE;

EID: 84960130006     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-016-0327-4     Document Type: Article

References (26)

1. 2 derivatives and their inhibitory activities to human platelet aggregation. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:279–81.
2. Nishio S, Matsuura H, Kanai N, Fukatsu Y, Hirano T, Nishikawa N, Kameoka K, Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol. 1988;47:1–10.
3. Kajikawa N, Nogimori K, Murata T, Nishio S, Uchiyama S. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Drug Res. 1989;39:495–9.
4. Nishio S, Kurumatani H. Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue. Nihon Yakurigaku Zasshi. 2001;117:123–30.
5. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest. 2005;128:709–13.
6. Fujitani K, Kambayashi J, Murata K, Yano Y, Shinozaki K, Yukawa M, Sakon M, Murata T, Kawasaki T, Shiba E, et al. Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol. Pharmacol Res. 1995;31:121–5.
7. Warot D, Berlin I, Aymard G, Ankri A, Fabry C, Besse B, Lechat P, Diquet B. Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. Fundam Clin Pharmacol. 2000;14:231–6.
8. Matsumoto K, Tajima A, Hirano Y, Ohno K, Yuge T, Hamasaki T, Hase T, Horiba M. Pharmacokinetics and biotransformation of beraprost sodium IV: metabolism of beraprost sodium in rat. Drug Metab Pharmacokinet. 1989;4:755–68.
9. Hirano Y, Matsumoto K, Tajima A, Ohno K, Yuge T, Hamasaki T, Hase T, Horiba M. Pharmacokinetics and biotransformation of beraprost sodium VI: metabolism and excretion of beraprost sodium in dog. Drug Metab Pharmacokinet. 1989;4:779–92.
10. Fukazawa T, Yajima K, Miyamoto Y. Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008;128:1459–65.
11. Zhang L, Zhang Y, Strong JM, Reynolds K, Huang S-M. Regulatory perspective on transporter-based interactions. Xenobiotica. 2008;38:709–24.
12. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36. doi:10.1038/nrd3028.
13. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol. 2013;9:459–72. doi:10.1517/17425255.2013.759210.14.
14. Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78:587–98.
15. Dingemanse J, van Giersbergen PL, Patat A, Nilsson PN. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther. 2010;15:157–63.
16. Walshaw PE, McCauley FA, Wilson TW. Diuretic and non-diuretic actions of furosemide: effects of probenecid. Clin Invest Med. 1992;15:82–7.
17. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol. 2001;419:113–20.
18. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T. Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000;275:831–8.
19. 2 on multidrug resistance transporters in human placental cells. Drug Metab Dispos. 2014;42:2077–86.
20. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004;94:197–202.
21. Kato R, Uji Y, Matsumoto K. Phase I study of beraprost sodium (TRK-100), a prostacyclin derivative- single oral administration study. Jpn J Clin Pharmacol Ther. 1989;20:515–27.
22. Gotzkowsky SK, Kumar P, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. J Cardiovasc Pharmacol. 2013;61:444–51.
23. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 2011;71:3029–41.
24. Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35:1400–7.
25. Matsumoto K, Tajima A, Hirano Y, Ohno K, Yuge T, Hamasaki T, Hase T, Horiba M. Pharmacokinetics and biotransformation of beraprost sodium I: plasma level profile of beraprost sodium in rat. Drug Metab Pharmacokinet. 1989;4:713–25.
26. Matsumoto K, Tajima A, Hirano Y, Ohno K, Yuge T, Hamasaki T, Hase T, Horiba M. Pharmacokinetics and biotransformation of beraprost sodium II: absorption, distribution and excretion after single administration of beraprost sodium in rat. Drug Metab Pharmacokinet. 1989;4:727–43.